Allurion Technologies Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Allurion Technologies Inc. (NYSE: ALUR) develops and commercializes innovative weight loss solutions focused on ending obesity through a comprehensive platform that combines medical devices, digital therapeutics, and behavioral support; the company offers the Allurion Program, featuring the Allurion Gastric Balloon—a swallowable, procedure-less intragastric balloon administered without surgery, endoscopy, or anesthesia that deflates after approximately four months and passes naturally; the Allurion Virtual Care Suite, including the Allurion Mobile App for patient engagement with behavior change programs in multiple languages, Allurion Insights powered by the Iris AI Platform for healthcare providers, and connected devices such as the Allurion Connected Scale and Health Tracker for remote monitoring. Founded in 2009 and headquartered in Natick, Massachusetts, Allurion operates primarily in Europe, including Spain and France, as well as Turkey, Canada, Brazil, and over 50 countries across six continents, targeting overweight and obese patients through clinics, bariatric specialists, and distribution partners. Recent developments include a November 2025 strategic distribution partnership with ProSurg Medical in Brazil to advance metabolically healthy weight loss approaches; a new strategic direction announced in August 2025 emphasizing low-dose GLP-1 combination therapies with the Allurion Program to preserve muscle mass, alongside a signed term sheet for potential GLP-1 drug-eluting balloon development and distribution expansion; successful FDA acceptance of its Premarket Approval application for the Allurion Balloon with substantive review underway following a Day-100 meeting; entry into a transaction to exchange all outstanding debt, positioning the company to become debt-free; and initial clinical results on combining the program with low-dose tirzepatide to optimize GLP-1 adherence.
Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum
Allurion Technologies, Inc. (NYSE:ALUR) Short Interest Up 124.0% in February
Allurion Advances Plan to Regain Listing Compliance
Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy
NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)
GN Store Nord (OTCMKTS:GNNDY) and Allurion Technologies (NYSE:ALUR) Financial Survey
Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)
Allurion Technologies (NYSE:ALUR) & CeriBell (NASDAQ:CBLL) Head-To-Head Survey
Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
Allurion Receives U.S. FDA Approval
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
Contrasting Aurora Cannabis (NASDAQ:ACB) & Allurion Technologies (NYSE:ALUR)
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Allurion Technologies (NYSE:ALUR) Shares Down 0.6% – Here’s What Happened
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
4 Medical Product Stocks to Watch From a Challenging Industry